GlassScriptPhysician profile
Edward Lawrence Langan
NPI 1598837767
$3,605.78
in general payments reported to CMS, 2019-2025
33 companies · $637 in 2025
The $637 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $257 · 2021: $376 · 2022: $510 · 2023: $365 · 2024: $524 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,038.11 | 2019-2025 | |
| Astellas Pharma US INC | $354.07 | 2022-2025 | Veozah |
| Mayne Pharma Commercial LLC | $292.41 | 2023-2025 | |
| Biogen, INC. | $244.69 | 2021-2025 | Zurzuvae |
| Amgen INC. | $229.34 | 2019 | |
| Coopersurgical, INC. | $182.08 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $176.58 | 2023-2025 | |
| Organon LLC | $95.10 | 2021-2024 | |
| Smith+Nephew, INC. | $85.31 | 2019-2024 | Pico 7 |
| Exeltis, USA INC. | $81.07 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $80.21 | 2019-2022 | |
| Ethicon US, LLC | $64.29 | 2022 | |
| Roche Diagnostics Corporation | $63.04 | 2019 | |
| Merck Sharp & Dohme LLC | $62.40 | 2019-2020 | |
| Baxter Healthcare | $50.21 | 2019-2025 | Tisseel |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $48.24 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $47.58 | 2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $46.13 | 2024 | |
| Amag Pharmaceuticals, INC. | $41.31 | 2019-2021 | |
| Medtronic, INC. | $37.46 | 2022 | |
| Sumitomo Pharma America, INC. | $35.04 | 2023-2024 | Myfembree |
| Intuitive Surgical, INC. | $31.36 | 2024 | |
| Astellas Pharma Global Development | $28.48 | 2024 | Veozah |
| Kci USA, INC. | $26.16 | 2020 | |
| Davol INC. | $25.21 | 2025 | Arista |
| Boston Scientific Corporation | $23.52 | 2023 | Advantage System |
| Medicem INC. | $20.52 | 2020 | |
| Evofem Biosciences, INC. | $20.29 | 2022 | |
| Convatec INC. | $17.98 | 2025 | |
| Dysis Medical, INC. | $17.17 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.38 | 2019 | |
| Hologic Sales and Service, LLC | $14.35 | 2020 | |
| Mylan Pharmaceuticals INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Langan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.